[Chinese Guidelines for the diagnosis, treatment, prophylaxis and management of pulmonary thromboembolism (2025 edition)].

Pulmonary thromboembolism (PTE) is a major clinical manifestation of venous thromboembolism (VTE), characterized pathologically by thrombotic obstruction of the pulmonary arteries or their branches, resulting in hemodynamic disturbances and impaired gas exchange. In severe cases, PTE may lead to right heart failure or even sudden death. In recent years, diagnostic and therapeutic capabilities for PTE in China have significantly improved. However, disparities remain across different regions, healthcare institutions, and clinical departments with respect to early identification, standardized prevention and treatment, and multidisciplinary collaboration. To enhance clinical practice, the Pulmonary Embolism and Pulmonary Vascular Disease Group of the Chinese Thoracic Society, the Pulmonary Vascular Disease Working Group of Chinese Association of Chest Physicians, and the National Cooperative Group for the Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Diseases jointly convened a multidisciplinary panel of experts. Based on both domestic and international evidence from evidence-based medicine and using the Delphi method, the Chinese Guidelines for the Diagnosis, Treatment, Prevention, and Management of Pulmonary Thromboembolism (2025) have been developed. These guidelines cover the definition, epidemiology, risk factors, diagnostic strategies, risk stratification, comprehensive scenario-based acute phase management strategies, management of special clinical conditions, long-term follow-up and preventive measures. The aim is to establish a standardized PTE management system suited to the national conditions and to promote consistent development of PTE prevention and treatment capabilities across all levels of healthcare institutions.